128 related articles for article (PubMed ID: 1695630)
1. Mapping of the prekallikrein-binding site of human H-kininogen by ligand screening of lambda gt11 expression libraries. Mimicking of the predicted binding site by anti-idiotypic antibodies.
Vogel R; Kaufmann J; Chung DW; Kellermann J; Müller-Esterl W
J Biol Chem; 1990 Jul; 265(21):12494-502. PubMed ID: 1695630
[TBL] [Abstract][Full Text] [Related]
2. Mapping of the high molecular weight kininogen binding site of prekallikrein. Evidence for a discontinuous epitope formed by distinct segments of the prekallikrein heavy chain.
Herwald H; Jahnen-Dechent W; Alla SA; Hock J; Bouma BN; Müller-Esterl W
J Biol Chem; 1993 Jul; 268(19):14527-35. PubMed ID: 7686159
[TBL] [Abstract][Full Text] [Related]
3. Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4.
Herwald H; Renné T; Meijers JC; Chung DW; Page JD; Colman RW; Müller-Esterl W
J Biol Chem; 1996 May; 271(22):13061-7. PubMed ID: 8662705
[TBL] [Abstract][Full Text] [Related]
4. High molecular weight kininogen-binding site of prekallikrein probed by monoclonal antibodies.
Hock J; Vogel R; Linke RP; Müller-Esterl W
J Biol Chem; 1990 Jul; 265(20):12005-11. PubMed ID: 1694851
[TBL] [Abstract][Full Text] [Related]
5. Structural dissection of the multidomain kininogens. Fine mapping of the target epitopes of antibodies interfering with their functional properties.
Kaufmann J; Haasemann M; Modrow S; Müller-Esterl W
J Biol Chem; 1993 Apr; 268(12):9079-91. PubMed ID: 7682558
[TBL] [Abstract][Full Text] [Related]
6. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI.
Tait JF; Fujikawa K
J Biol Chem; 1987 Aug; 262(24):11651-6. PubMed ID: 3650269
[TBL] [Abstract][Full Text] [Related]
7. The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy.
Weisel JW; Nagaswami C; Woodhead JL; DeLa Cadena RA; Page JD; Colman RW
J Biol Chem; 1994 Apr; 269(13):10100-6. PubMed ID: 8144509
[TBL] [Abstract][Full Text] [Related]
8. Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain.
Thompson RE; Mandle R; Kaplan AP
Proc Natl Acad Sci U S A; 1979 Oct; 76(10):4862-6. PubMed ID: 291905
[TBL] [Abstract][Full Text] [Related]
9. Solution phase conformation studies of the prekallikrein binding domain of high molecular weight kininogen.
Scarsdale JN; Harris RB
J Protein Chem; 1990 Oct; 9(5):647-59. PubMed ID: 2085389
[TBL] [Abstract][Full Text] [Related]
10. Calorimetric and spectroscopic examination of the solution phase structures of prekallikrein binding domain peptides of high molecular weight kininogen.
You JL; Scarsdale JN; Harris RB
J Protein Chem; 1991 Jun; 10(3):301-11. PubMed ID: 1910462
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor.
Herwald H; Dedio J; Kellner R; Loos M; Müller-Esterl W
J Biol Chem; 1996 May; 271(22):13040-7. PubMed ID: 8662673
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody to human high-molecular-weight kininogen recognizes its prekallikrein binding site and inhibits its coagulant activity.
Reddigari SR; Kaplan AP
Blood; 1989 Aug; 74(2):695-702. PubMed ID: 2752143
[TBL] [Abstract][Full Text] [Related]
13. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2.
Renné T; Dedio J; Meijers JC; Chung D; Müller-Esterl W
J Biol Chem; 1999 Sep; 274(36):25777-84. PubMed ID: 10464316
[TBL] [Abstract][Full Text] [Related]
14. Localization of distinct functional domains on prekallikrein for interaction with both high molecular weight kininogen and activated factor XII in a 28-kDa fragment (amino acids 141-371).
Page JD; Colman RW
J Biol Chem; 1991 May; 266(13):8143-8. PubMed ID: 1708772
[TBL] [Abstract][Full Text] [Related]
15. Fine mapping of the H-kininogen binding site in plasma prekallikrein apple domain 2.
Renné T; Sugiyama A; Gailani D; Jahnen-Dechent W; Walter U; Müller-Esterl W
Int Immunopharmacol; 2002 Dec; 2(13-14):1867-73. PubMed ID: 12489801
[TBL] [Abstract][Full Text] [Related]
16. Mapping of the H-kininogen binding site exposed by the prekallikrein heavy chain.
Herwald H; Hock H; Jahnen-Dechent W; Müller-Esterl W
Agents Actions Suppl; 1992; 38 ( Pt 1)():225-32. PubMed ID: 1466274
[No Abstract] [Full Text] [Related]
17. Conformational analysis of synthetic peptides encompassing the factor XI and prekallikrein overlapping binding domains of high molecular weight kininogen.
You JL; Page JD; Scarsdale JN; Colman RW; Harris RB
Peptides; 1993; 14(5):867-76. PubMed ID: 8284263
[TBL] [Abstract][Full Text] [Related]
18. Immunovisualisation of plasma prekallikrein and H-kininogen on human neutrophils and in human hepatocytes.
Henderson LM; Figueroa CD; Muller-Esterl W; Stain A; Bhoola KD
Agents Actions Suppl; 1992; 38 ( Pt 1)():590-4. PubMed ID: 1466300
[TBL] [Abstract][Full Text] [Related]
19. Interaction of factor XII, high-molecular-weight (HMW) kininogen and prekallikrein with sulfatide: analysis by fluorescence polarization.
Shimada T; Kato H; Maeda H; Iwanaga S
J Biochem; 1985 Jun; 97(6):1637-44. PubMed ID: 3928613
[TBL] [Abstract][Full Text] [Related]
20. Molecular cloning of cDNAs for mouse low-molecular-weight and high-molecular-weight prekininogens.
Takano M; Kondo J; Yayama K; Otani M; Sano K; Okamoto H
Biochim Biophys Acta; 1997 May; 1352(2):222-30. PubMed ID: 9199253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
